Kasper Møller
Chief Tech/Sci/R&D Officer chez MOLMED S.P.A.
Profil
Kasper Møller is currently the Chief Technical Officer at AGC Biologics SpA since 2019.
He is also the Chief Technology Officer at AGC Biologics A since 2006.
Previously, he worked as a Faculty Member at the Technical University of Denmark.
Dr. Møller holds a doctorate degree from the Technical University of Denmark, which he obtained in 2001.
He also has a graduate degree from Washington University School of Medicine.
Postes actifs de Kasper Møller
| Sociétés | Poste | Début |
|---|---|---|
| MOLMED S.P.A. | Chief Tech/Sci/R&D Officer | 01/06/2019 |
AGC Biologics A/S
 AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Chief Tech/Sci/R&D Officer | 04/06/2019 |
Anciens postes connus de Kasper Møller
| Sociétés | Poste | Fin |
|---|---|---|
| Technical University of Denmark | Corporate Officer/Principal | - |
Formation de Kasper Møller
| Technical University of Denmark | Doctorate Degree |
| Washington University School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
AGC Biologics A/S
AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark. | Health Technology |
